Exane BNP Paribas Downgrades Medical Properties Trust to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Exane BNP Paribas analyst Nate Crossett has downgraded Medical Properties Trust (NYSE:MPW) from Outperform to Neutral and lowered the price target from $6 to $4.
July 02, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Exane BNP Paribas has downgraded Medical Properties Trust from Outperform to Neutral and reduced the price target from $6 to $4.
The downgrade from Outperform to Neutral and the significant reduction in the price target from $6 to $4 by a reputable analyst is likely to negatively impact investor sentiment and the stock price of Medical Properties Trust in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100